65,437 trials
Alcohol Dependence
Primary: Time to Relapse to Heavy Drinking as Defined by Having 5 or More Drinks in a Sitting for Men and Will be Assessed Using the Time Line Follow Back for Recent Drinking…
Ankylosing Spondylitis
Primary: Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 336 Hours After the Single Infusion of BCD-055/Remicade — 26282582; 25914888 (ng/ml)*hour
Cancer
Primary: Treatment Difference in Duration of Cardiac Ventricular Depolarization and Repolarization Interval (QT) in Fridericia-corrected QT Interval (QTcF) Values Between Placebo…
Lupus Erythematosus, Discoid · Lupus Erythematosus, Systemic
Primary: Decrease in the Total Combined Erythema and Scaling Score (Minimum of 0 and Maximum of 65) of All Treated Lesions. — 22.2; 27.8 percentage of subjects
Hepatitis C, Chronic
Primary: Number of Pegasys and Ribavirin Therapy Completers — 3; 23; 2; 23 Participants
Spinal Fusion · Cardiopulmonary Bypass
Primary: International Normalized Ratio (INR) on CoaguChek — 1.11; 4.6 ratio
Essential Thrombocythemia (ET)
Primary: Change From Baseline in Platelet Count at Final Assessment — 1021.6; -346.2 10^9 platelets per liter (10^9/L)
Malignant Melanoma
Primary: Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 From 0 to 8 Hours on Day 1 — 37.54 h*μg/mL
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change in Placebo Corrected Change From Baseline QTc and J-Tpeakc Intervals on the ECG Measured in Milliseconds When Dofetilide is Administered With Mexiletine or…
Non Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 70.9 % of participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Self-Reported Respiratory-Specific Quality of Life — -0.8; -3.2 units on a scale — p=0.142
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving Low Disease Activity After 6 Months of Treatment — 57.52 percentage of participants — p=0.0237
Obesity · Sedentary
Primary: Neonatal Adiposity — 11.2; 12.4 % fat
Adult Refractory Complex Partial Seizures
Primary: Mean Change From Reference Value in Field Width as Measured by 30-2 SITA Fast in Field Sensitivity (Mean Deviation - MD in dB) — -0.28; -0.24; -0.14; -0.13 dB
Lip Augmentation
Primary: Percentage of Subjects With ≥1-Point Improvement on the Investigator Assessed 5-point Lip Fullness Scale 2 (LFS2) — 79.1; 26.1 Percentage of Subjects